Embecta Corp (EMBC)
12.37
-0.06
(-0.48%)
USD |
NASDAQ |
May 31, 16:00
12.36
-0.01
(-0.08%)
After-Hours: 20:00
Embecta Enterprise Value: 2.015B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 2.015B |
| May 30, 2024 | 2.018B |
| May 29, 2024 | 2.036B |
| May 28, 2024 | 2.056B |
| May 24, 2024 | 2.059B |
| May 23, 2024 | 2.051B |
| May 22, 2024 | 2.084B |
| May 21, 2024 | 2.091B |
| May 20, 2024 | 2.105B |
| May 17, 2024 | 2.135B |
| May 16, 2024 | 2.120B |
| May 15, 2024 | 2.094B |
| May 14, 2024 | 2.143B |
| May 13, 2024 | 2.119B |
| May 10, 2024 | 2.123B |
| May 09, 2024 | 2.118B |
| May 08, 2024 | 1.894B |
| May 07, 2024 | 1.910B |
| May 06, 2024 | 1.901B |
| May 03, 2024 | 1.887B |
| May 02, 2024 | 1.891B |
| May 01, 2024 | 1.886B |
| April 30, 2024 | 1.886B |
| April 29, 2024 | 1.903B |
| April 26, 2024 | 1.896B |
| Date | Value |
|---|---|
| April 25, 2024 | 1.901B |
| April 24, 2024 | 1.929B |
| April 23, 2024 | 1.929B |
| April 22, 2024 | 1.920B |
| April 19, 2024 | 1.914B |
| April 18, 2024 | 1.898B |
| April 17, 2024 | 1.892B |
| April 16, 2024 | 1.898B |
| April 15, 2024 | 1.912B |
| April 12, 2024 | 1.893B |
| April 11, 2024 | 1.936B |
| April 10, 2024 | 1.959B |
| April 09, 2024 | 1.983B |
| April 08, 2024 | 2.002B |
| April 05, 2024 | 2.037B |
| April 04, 2024 | 2.038B |
| April 03, 2024 | 2.031B |
| April 02, 2024 | 2.035B |
| April 01, 2024 | 2.057B |
| March 31, 2024 | 2.067B |
| March 28, 2024 | 2.068B |
| March 27, 2024 | 2.046B |
| March 26, 2024 | 2.015B |
| March 25, 2024 | 2.025B |
| March 22, 2024 | 2.018B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.886B
Minimum
Apr 30 2024
3.306B
Maximum
Dec 13 2022
2.628B
Average
2.740B
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 10.88M |
| Perspective Therapeutics Inc | 680.29M |
| Protalix BioTherapeutics Inc | 54.78M |
| Electromed Inc | 114.83M |
| Armata Pharmaceuticals Inc | 192.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 28.90M |
| Revenue (Quarterly) | 287.20M |
| Total Expenses (Quarterly) | 248.00M |
| EPS Diluted (Quarterly) | 0.50 |
| Gross Profit Margin (Quarterly) | 64.55% |
| Profit Margin (Quarterly) | 10.06% |
| Earnings Yield | 9.78% |
| Operating Earnings Yield | 23.01% |
| Normalized Earnings Yield | 9.782 |